Abstract
Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Current Drug Targets
Title:Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Volume: 18 Issue: 10
Author(s): Ping Duan, Lili Fan, Quansheng Gao, Bal Mukunda Silwal, Mulan Ren, Yang Shen*Wanglei Qu*
Affiliation:
- Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing 210009,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027,China
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Abstract: Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Export Options
About this article
Cite this article as:
Duan Ping, Fan Lili, Gao Quansheng, Silwal Mukunda Bal, Ren Mulan, Shen Yang*, Qu Wanglei*, Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170329095807
DOI https://dx.doi.org/10.2174/1389450118666170329095807 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Current Pharmaceutical Biotechnology Drugs Repurposing in High-Grade Serous Ovarian Cancer
Current Medicinal Chemistry Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions
Current Angiogenesis (Discontinued) Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Cancer and Stem Cells
Current Cancer Therapy Reviews A Phase I Study of OMN54 (Aneustatâ„¢) in Patients with Advanced Malignancies
Clinical Cancer Drugs Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Exosome as a Natural Gene Delivery Vector for Cancer Treatment
Current Cancer Drug Targets DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Most Promising Compounds for Treating COVID-19 and Recent Trends in Antimicrobial & Antifungal Agents
Current Topics in Medicinal Chemistry Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Progress in Synthesis and Antitumor Activities of Estradiol-linked Platinum Complex
Mini-Reviews in Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumor Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine